Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Polio vaccine and retroviruses.

Beale J, Horaud F.

Philos Trans R Soc Lond B Biol Sci. 2001 Jun 29;356(1410):841-3. Review.

2.

Karyology and tumorigenicity testing requirements: past, present and future.

Petricciani JC, Horaud FN.

Dev Biol Stand. 1998;93:5-13. Review.

PMID:
9737371
3.

Viral safety of biological products and the concept of validation.

Horaud F.

Dev Biol Stand. 1996;88:19-24. Review. No abstract available.

PMID:
9119135
4.

Viral safety of blood derivatives: an overview.

Horaud F.

Clin Ther. 1996;18 Suppl B:37-42. Review.

PMID:
8930440
5.

DNA, dragons and sanity.

Petricciani JC, Horaud FN.

Biologicals. 1995 Sep;23(3):233-8. Review. No abstract available.

PMID:
8527124
6.

Viral vaccines and residual cellular DNA.

Horaud F.

Biologicals. 1995 Sep;23(3):225-8. Review.

PMID:
8527122
7.

Viral iatrogenic contamination and safety of biologicals.

Horaud F.

Blood Coagul Fibrinolysis. 1995 Jul;6 Suppl 2:S5-9. Review.

PMID:
7495969
8.

An historical outline of the development of live poliovaccine and its non-target effects.

Horaud F.

Dev Biol Stand. 1995;84:117-22. No abstract available.

PMID:
7796943
9.

IABS International Meeting on Genetic Stability and Recombinant Product Consistency. 8-9 July, 1993, Imperial Palace Congress Centre, Annecy, France.

Horaud F, Lubiniecki AS, Robertson JS.

Biologicals. 1994 Mar;22(1):77-81. No abstract available.

PMID:
8068318
10.

A view on regulatory aspects of live viral vaccine safety.

Horaud F.

Dev Biol Stand. 1994;82:113-8.

PMID:
7958465
11.

Albert B. Sabin and the development of oral poliovaccine.

Horaud F.

Biologicals. 1993 Dec;21(4):311-6.

PMID:
8024745
12.

Albert B. Sabin.

Melnick JL, Horaud F.

Biologicals. 1993 Dec;21(4):297-303. No abstract available.

PMID:
8024743
13.

A mutation in the RNA polymerase of poliovirus type 1 contributes to attenuation in mice.

Tardy-Panit M, Blondel B, Martin A, Tekaia F, Horaud F, Delpeyroux F.

J Virol. 1993 Aug;67(8):4630-8.

15.

Ethical and safety considerations for the use in clinical trials of new attenuated poliovirus strains.

Horaud F.

Dev Biol Stand. 1993;78:149-54; discussion 154-5. No abstract available.

PMID:
8388825
16.

The safety of biologicals--old problem, new questions.

Horaud F.

Dev Biol Stand. 1993;80:3-5. No abstract available.

PMID:
8270113
17.

The EEC and the regulation of blood derivatives.

Horaud F.

Dev Biol Stand. 1993;81:273-6. Review. No abstract available.

PMID:
8174814
18.

Biologicals: an attempt at classification and its implication for the viral safety of products.

Horaud F.

Dev Biol Stand. 1993;81:17-24. Review. No abstract available.

PMID:
8174800
19.

Absence of viral sequences in the WHO-Vero Cell Bank. A collaborative study.

Horaud F.

Dev Biol Stand. 1992;76:43-6. No abstract available.

PMID:
1478353
20.
21.

Introductory remarks: viral safety of biologicals.

Horaud F.

Dev Biol Stand. 1991;75:3-7. Review. No abstract available.

PMID:
1794630
23.

Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature.

Christodoulou C, Colbere-Garapin F, Macadam A, Taffs LF, Marsden S, Minor P, Horaud F.

J Virol. 1990 Oct;64(10):4922-9.

24.

An immunoenzymatic test designed for the detection of small amounts of contaminant DNA in biological preparations.

Traincard F, Horaud F, Mazie JC, Guesdon JL.

Dev Biol Stand. 1990;71:181-4. No abstract available.

PMID:
2401383
25.

Poliovirus permissivity and specific receptor expression on human endothelial cells.

Couderc T, Barzu T, Horaud F, Crainic R.

Virology. 1990 Jan;174(1):95-102.

PMID:
2152997
26.

Molecular pathogenesis of neural lesions induced by poliovirus type 1.

Couderc T, Christodoulou C, Kopecka H, Marsden S, Taffs LF, Crainic R, Horaud F.

J Gen Virol. 1989 Nov;70 ( Pt 11):2907-18.

PMID:
2555432
27.

Molecular pathogenesis of type 2 poliovirus in mice.

Couderc T, Guinguene B, Horaud F, Aubert-Combiescu A, Crainic R.

Eur J Epidemiol. 1989 Sep;5(3):270-4.

PMID:
2551721
28.

Production of biologicals using large scale culture.

Bachmayer H, Barrett N, Griffiths JB, Horaud F.

Cytotechnology. 1989 Aug;2(Suppl 3):70-1. doi: 10.1007/BF02279729. No abstract available.

PMID:
22359034
29.

An insight into poliovirus biology.

Crainic R, Couderc T, Martin A, Wychowski C, Girard M, Horaud F.

Adv Exp Med Biol. 1989;257:61-6. Review. No abstract available.

PMID:
2482671
30.

Construction and characterization of hybrid hepatitis B antigen particles carrying a poliovirus immunogen.

Delpeyroux F, Crainic R, Blondel B, Horaud F, Van der Werf S, Girard M, Lagarde D, Mazert MC, Streeck RE.

Biochimie. 1988 Aug;70(8):1065-73.

PMID:
2465786
31.

Identification and characterization of a continuous neutralization epitope (C3) present on type 1 poliovirus.

Horaud F, Crainic R, Van der Werf S, Blondel B, Wichowski C, Akacem O, Bruneau P, Couillin P, Siffert O, Girard M.

Prog Med Virol. 1987;34:129-55. Review. No abstract available.

PMID:
2443945
32.

Antigenic and molecular properties of type 3 poliovirus responsible for an outbreak of poliomyelitis in a vaccinated population.

Magrath DI, Evans DM, Ferguson M, Schild GC, Minor PD, Horaud F, Crainic R, Stenvik M, Hovi T.

J Gen Virol. 1986 May;67 ( Pt 5):899-905.

PMID:
3009690
33.

Mutations conferring resistance to neutralization with monoclonal antibodies in type 1 poliovirus can be located outside or inside the antibody-binding site.

Blondel B, Crainic R, Fichot O, Dufraisse G, Candrea A, Diamond D, Girard M, Horaud F.

J Virol. 1986 Jan;57(1):81-90.

34.

Comparative expression of the hepatitis B surface antigen gene in biochemically transformed human, simian and murine cells.

Colbère-Garapin F, Horaud F, Kourilsky P, Garapin A.

J Gen Virol. 1985 Aug;66 ( Pt 8):1741-52.

PMID:
2991437
35.

A rabies vaccine produced in a non-tumorigenic rabbit cell line.

Sureau P, Perrin P, Horaud F.

Dev Biol Stand. 1985;60:133-9.

PMID:
4043531
36.

Stable HBV surface antigen expression by Vero cell clones after transfection.

Colbére-Garapin F, Horaud F, Kourilsky P, Garapin AC.

Dev Biol Stand. 1985;59:109-12.

PMID:
4007271
37.

Antigenic modification of attenuated Sabin type 1 poliovirus by in vitro passages at supraoptimal temperatures.

Crainic R, Blondel B, Candréa A, Dufraisse G, Horaud F.

Dev Biol Stand. 1985;60:343-7.

PMID:
2995173
38.

Mapping of type 1 poliovirus neutralization epitopes.

Blondel B, Crainic R, Dufraisse G, Candréa A, Horaud F.

Dev Biol Stand. 1985;60:337-42.

PMID:
2412917
39.

Antigenic variation of poliovirus studied by means of monoclonal antibodies.

Crainic R, Blondel B, Horaud F.

Rev Infect Dis. 1984 May-Jun;6 Suppl 2:S535-9.

PMID:
6204369
40.

Neutralization epitope patterns of poliovirus strains isolated from paralytic cases.

Crainic R, Blondel B, Aubert-Combiescu A, Beytout D, Couillin P, Candrea A, Boué A, Horaud F.

Dev Biol Stand. 1984;57:165-70.

PMID:
6084607
41.

Serologic survey of antibodies to cytomegalovirus in women and infants in Lima, Peru.

Palacios O, Cabau N, Horaud F, Plotkin S.

J Infect Dis. 1983 Apr;147(4):777. No abstract available.

PMID:
6302175
42.

Induction of neutralizing antibodies by type 1 poliovirus VP1 capsid polypeptide.

Crainic R, Blondel B, Horaud F.

Dev Biol Stand. 1983;55:185-9.

PMID:
6329856

Supplemental Content

Loading ...
Support Center